Since emerging in December 2019, coronavirus disease 2019 (Covid-19) has developed into an unprecedented global pandemic. The causative pathogen, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has the potential to cause a wide range of clinical syndromes, from fever, dyspnoea and cough to respiratory failure and cardiac injury necessitating critical care support. A number of patients have a more indolent clinical course and can be safely managed in the community. Characterising the clinical course of Covid-19 infection in the oncology population and distinguishing this from other acute oncology presentations which can mimic Covid-19 is a key unmet research need. Current standard of care for monitoring patients at high risk of chemotherapy associated neutropenic sepsis involves asking them to contact their cancer centre when they feel unwell or develop a fever. No standard of care for monitoring ambulatory Covid-19 patients has yet been established. We hypothesise that using wearable biosensors to detect patients who exhibit 'red flags' for sepsis or deterioration due to Covid-19 may allow earlier assessment and intervention. There is no current evidence for wearable biosensors in ambulatory patients receiving chemotherapy, and there is no existing research into this proposed use of biosensors in patients with suspected or confirmed Covid-19 infection. In order to justify performing a randomised controlled study comparing standard of care with biosensor driven monitoring it is important to establish the tolerability and validity of these devices. We aim to collect patient reported outcome measures (PROMs) on tolerability and assess the reliability of data transmission to a central data collection server. We will also perform an initial analysis of physiological data and correlation with clinical events
This is a pilot, single arm, open label feasibility study. This is a single centre trial
based in a large tertiary cancer centre which treats patients across all solid and
haematological malignancies. Patients will be recruited from all disease groups.
Patients who present with symptoms suspicious for Covid-19 who the admitting clinicians deems
appropriate for outpatient management will be considered for this study.
Patients who are enrolled will undergo continuous physiological monitoring for up to three
weeks. This includes continuous monitoring of heart rate, respiratory rate, temperature,
activity levels (by accelerometer measurement) and twice daily pulse oximetry. The
physiological data will not be reviewed in real time by clinicians and therefore will not be
used to alter patients' standard care. The pulse oximetry data will be visible to patients
who will be given clear guidelines to follow with regards to contacting the cancer centre
hotline should values deviate from baseline.
In the pilot phase of RECAP 10-30 patients will each be monitored for up to 3 weeks and the
following endpoints will be addressed:
Physiological trends and interactions predictive of clinical deterioration due to COVID-19
(Co-primary endpoint) Reliability of biosensor data collection/transmission using digital
technology from patients self-isolating at home (Co-primary endpoint) Acceptability and
tolerability of wearable biosensors and continuous monitoring If the pilot phase is
successful we will move to a phase II study in a larger number of patients where the
objective will be to refine a physiological signature predictive of clinical deterioration in
COVID-19 patients so that early hospitalisation and relevant medical interventions can be
arranged.
Device: Patient Status Engine
Wearable sensors
Inclusion Criteria:
1. Participants are capable of giving informed consent
2. Male or female aged 18 or over
3. Diagnosis of any solid tumour or haematological malignancy meeting one of the
following criteria:
- Current malignant diagnosis
- Received anti-cancer treatment within the last two years
4. Emergency presentation to hospital with symptoms consistent with Covid-19 deemed to
meet the criteria for Covid-19 testing by admitting clinician.
5. Deemed by the admitting clinician to be suitable for outpatient management of
suspected Covid-19.
6. Stable oxygen saturations of 95% or higher at time of emergency presentation.
7. Able to complete tolerability questionnaire.
8. Able and willing to comply with twice daily pulse oximetry monitoring as outlined in
section 6 of the protocol.
9. ECOG-PS <4
10. Life expectancy of greater than three months as assessed by screening investigator
from review of electronic patient record.
Exclusion Criteria:
1. Patients hospitalized for more than 24 hours at initial presentation with symptoms
consistent with Covid-19.
2. Pregnant patients.
3. Patients unable to give informed consent.
4. Presence of ulceration or pre-existing skin rash at site of device application (left
precordium and axillae). If only one axilla affected this is not an exclusion
criterion if patient is happy to apply temperature sensor to the other axilla.
5. Radiotherapy to the left chest wall either during or within the six months preceding
the study. Plans for subsequent radiotherapy to commence after study completion are
not an exclusion criterion. If only one axilla is within the planned radiotherapy
field and patient is happy to apply temperature sensor to the other axilla this is not
an exclusion criteria.
6. History of allergy or contact dermatitis to medical adhesives e.g sticking plasters,
ECG electrodes.
7. Patients with pacemakers, implantable defibrillators or neurostimulators.
8. Patients who are currently receiving treatment as part of a clinical study or have had
their end of treatment visit for another clinical study less than 30 days prior to the
study enrollment visit.
The Christie NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom
Investigator: Wes Dale
Contact: 1619187902
Wes.dale@christie.nhs.uk
Wes Dale
01614463000 - 7902
wes.dale@christie.nhs.uk
John Radford, Principal Investigator
The University of Manchester